FindTrial
Sign In

Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes

Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naïve Japanese patients with type 2 diabetes - Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000011243
Enrollment
20
Registered
2013-07-22
Start date
2012-12-02
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-na&amp

Interventions

They were randomized to receive the combination of mitiglinide and voglibose Sitagliptin was administered at a dose of 50 mg once daily after breakfast for 8 weeks (S-first group), while the combinati

Sponsors

St. Marianna University School of Medicine, Department of Internal Medicine, Division of Metabolism and Endocrinology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria were stable, but slightly inadequate, glycemic control (6.2HbA1c7.5%, and variation of HbA1c by <0.5% within 3 months before recruitment) without the use of insulin or oral antidiabetic drugs.

Exclusion criteria

Exclusion criteria: The exclusion criteria were pregnancy, severe illness, anemia, renal failure (serum creatinine>2.0 mg/dL) and/or overt proteinuria, chronic liver disease, thyroid disease, and malignancy.

Design outcomes

Primary

MeasureTime frame
Levels of HbA1c, glycoalbumin (GA), and 1,5-anhydroglucitol (1,5-AG) were measured at base line and 8weeks.—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026